

Point-by-point response letter for the reviewers

Reviewer #1:

This was an import study for the treatment of mCRC with RAS mutant tumors. Authors indicated that triplet-regimen plus bevacizumab might be the preferred regimen for left-sided mCRC with RAS mutations. The results and interpretation of author's research were different from other study published before. However I would prefer to know further information about the discussions: First, please supplement the reference for "Although a recent study reported that FOLFOXIRI plus bevacizumab may be regarded as a preferred option for only right-sided mCRC" (the last 3-4 line, Page 7). Second, could please the authors explain the possible reasons why their results were opposite to "a recent results" above?

We really appreciate the reviewer's valuable comments and suggestions.

According to the reviewer's indication, we added the reference on the page 7.

Also, we added the following sentences to explain the possible reasons why our results or other study results were opposite to the TRIBE data (on page 7):

"FOLFOXIRI plus bevacizumab was not beneficial in left-sided tumors in the TRIBE trial, while FOLFOXIRI plus bevacizumab appeared to be better compared to FOLFOX plus bevacizumab in left-sided tumors in other 2 trials. Types of backbone chemotherapy may affect the results of sub-analyses by tumor sidedness."